SCHEMBL5387032

SCHEMBL5387032

NC(=O)c1ccccc1NCCc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 4/20 0.63
PKM P14618 2/20 0.63
RPS6KB1 P23443 1/20 0.55
AKT1 P31749 1/20 0.55
ALDH1A1 P00352 3/20 0.55
MAPT P10636 2/20 0.55
HPGD P15428 2/20 0.55
LMNA P02545 1/20 0.55
KDM6B O15054 1/20 0.52
KDM4C Q9H3R0 1/20 0.52
KMT2A Q03164 2/20 0.52
KDM4E B2RXH2 2/20 0.51
SIRT1 Q96EB6 2/20 0.51
RXFP1 Q9HBX9 1/20 0.51
ASPH Q12797 1/20 0.50
RIOX2 Q8IUF8 1/20 0.50
KDM8 Q8N371 1/20 0.50
HSD17B10 Q99714 1/20 0.50
AGTR1 P30556 2/20 0.49
MEN1 O00255 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10839345 0.88 KDM6B (0.55) SIRT2PKMRPS6KB1AKT1ALDH1A1
Enfenamic Acid SCHEMBL25191 0.86 KDM6B (0.68) PKMALDH1A1MAPTHPGDLMNA
Enfenamic Acid SCHEMBL10935569 0.85 KDM6B (0.66) PKMALDH1A1MAPTHPGDLMNA
SCHEMBL2754257 0.84 HSD17B10 (0.63) SIRT2RPS6KB1AKT1ALDH1A1HPGD
SCHEMBL30311518 0.84 HSD17B10 (0.63) SIRT2RPS6KB1AKT1ALDH1A1HPGD
SCHEMBL12608931 0.83 RXFP1 (0.54) PKMALDH1A1MAPTHPGDLMNA
SCHEMBL3716882 0.82 KDM4C (0.67) PKMRPS6KB1AKT1KDM6BKDM4C
Enfenamic Acid SCHEMBL10935566 0.82 MAPT (0.53) PKMALDH1A1MAPTHPGDLMNA
SCHEMBL11454827 0.82 SIRT2 (0.51) SIRT2PKMALDH1A1MAPTHPGD
Hydrochloric Acid SCHEMBL11457102 0.81 SIRT2 (0.50) SIRT2PKMALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7253198-B2 Hydroxyethylamine derivatives for the treatment of Alzheimer's disease GLAXO GROUP LIMITED (GB) 2007-08-07 US disclosed
US-20060025459-A1 Hydroxyethylamine derivatives for the treatment of alzheimer's disease GLAXO GROUP LIMITED (GB) 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025459-A1 Hydroxyethylamine derivatives for the treatment of alzheimer's disease BACE2, PSEN2, BACE1 SIRT2 1101/4885PKM 1448/4885RPS6KB1 1209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.